OssDsign AB September 26th, 2023 announced a strategic shift to focus its operations on the orthobiologics business in the U.S. The new strategy means that OssDsign will become a pure play orthobiologics company focusing on the nanosynthetic bone graft OssDsign Catalyst.
OssDsign Catalyst can be used in multiple applications in the body, and was recently the first synthetic bone graft to be cleared to market for use in spinal interbody fusions based on bone graft data alone. A breakthrough in nanosynthetic bone grafting, orthobiologics
According to the Company's Articles of Association, the Board of Directors shall consist of a minimum of three and a maximum of seven Board members without deputy directors. OssDsign, Catalyst, orthobiologics
At the Annual General Meeting 2022, the registered audit firm Ernst & Young AB was new-elected to OssDsign’s auditor. Authorized Public Accountant Oskar Wall is Chief Auditor.
OssDsign) releases its Q3 2026 interim financial report, available as a downloadable PDF on its website. The report provides updates on the company’s performance for the quarter.
OssDsign enrolls over 400 patients in the PROPEL registry, a multi-center study assessing its spine fusion product OssDsign Catalyst. Early results show an 88.4% fusion rate at 12 months among the first 108 patients, covering complex cases. The registry, launched in March 2022, continues to expand its participant base.
OssDsign releases its **Annual Report 2025**, detailing financial and operational performance for the year. The document is available as a downloadable PDF on the company’s official website, **ossdsign.com**. Shareholders and stakeholders can access the full report through the press release attachment.
OssDsign reports strong growth in 2025, leveraging real-world data to prepare for expansion into the U.S. market. The company highlights operational progress and data-driven strategies as key enablers for its international scaling plans. Financial and performance details are outlined in the published year-end report.
OssDsign names **Mark Waugh** as its new CEO, effective January 1, 2026. Waugh previously led commercial operations at Medacta USA and brings over two decades of experience in orthopedic sales, marketing, and commercial strategy across the U.S. and Europe. His appointment follows a tenure in senior roles within the global orthopedic industry.
OssDsign secures a strategic agreement with an Integrated Delivery Network (IDN) in the Western U.S., expanding its commercial reach and unlocking its largest regional sales opportunity. The partnership targets growth in healthcare delivery networks, leveraging OssDsign’s existing solutions. This marks the company’s most significant regional expansion initiative to date.
OssDsign reports an **88.4% spinal fusion success rate** in its **PROPEL registry**, covering 108 patients with complex conditions—including high BMI, prior failed surgeries, smoking histories, and multi-level procedures. The data, from real-world use of its **Catalyst®** product, highlights strong performance in difficult clinical scenarios. Results stem from a prospective, multi-center study published in June 2025.
OssDsign raises approximately SEK 158 million through a directed share issue of 11.5 million shares at SEK 13.75 per share. The transaction, led by DNB Carnegie, follows an accelerated book-building process. The funds are received before deducting transaction costs.
OssDsign reports that **1,000 patients in the U.S. have received its nanosynthetic bone graft, OssDsign Catalyst**, marking a milestone in adoption. The company attributes the growth to rising product awareness among medical professionals. Demand continues to rise as more healthcare providers incorporate the graft into treatments.